Vaccine developer Chimerix has added life sciences industry veteran Timothy Trost to its management team.
Durham, North Carolina-based Chimerix has named Trost to the newly created position of senior vice president, chief financial officer. Before coming to Chimerix, Trost was CFO of Argos Therapeutics in Research Triangle Park. Trost’s 30-year career in the industry includes his role as CFO at InteCardia, a venture-backed cardiac imaging company. Trost helped negotiate the sale of InteCardia to Syncor International, now a part of Cardinal Health (NYSE: CAH).
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Trost is no stranger to Chimerix. CEO Kenneth Moch noted in a prepared statement that Trost has been consulting for Chimerix since last fall and helped secure the company’s recent $45 million series F round of financing. He also worked on securing Chimerix’s contract with the Biomedical Advanced Research and Development Authority, or BARDA. The agreement, in which Chimerix will develop a bioterrorism countermeasure to smallpox, could be worth more than $81 million to Chimerix if the company’s development efforts are successful.
Chimerix’s lead candidate is CMX001, which is being developed as a potential broad spectrum antiviral agent. The compound has been studied as a treatment for cytomegalovirus, a virus that can severely sicken patients with already compromised immune systems. It has also shown potential for treating smallpox, which although eradicated, is still considered a bioterrorism threat.
Related articles
- Antiviral pharma Chimerix raises $45M in series F venture round (medcitynews.com)
Health Benefit Consultants, Share Your Expert Insights in Our Survey
Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.
